Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Oxytocin on OSA
NCT02564068Phase 1Completed
- Sponsor
- George Washington University
- Start
- May 2015
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxytocin nasal spray in obstructive sleep apnea (OSA) (2 arms), sponsored by George Washington University. Primary endpoints: Frequency of Hypopnea Events and Frequency of Apnea Events. Started May 2015; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02564068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564068.